Table 3.

Univariate and multivariate analyses of prognostic factors for overall survival in whole-cohort AML patients.

Variables			OS				LFS
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)
HSPG2 expression (high vs. low)	<0.001	4.683 (1.848–11.869)	0.004	3.963 (1.464–7.042)	0.047	2.025 (1.010–3.482)	0.302	–
Age (≥60 vs. <60)	0.005	2.338 (1.296–4.217)	0.798	–	0.214	1.465 (0.802–2.675)	–	–
Sex (male vs. female)	0.376	1.302 (0.726–2.332)	–	–	0.638	1.155 (0.634–2.105)	–	–
WBC (≥30 vs. <30)	0.001	2.831 (1.563–5.127)	0.113	–	0.004	2.550 (1.348–4.824)	0.026	1.969 (1.085–3.571)
BM Blasts (≥70% vs. <70%)	0.081	1.739 (0.935–3.236)	–	–	0.771	1.110 (0.552–2.232)	–	–
Treatment regimen	0.001	6.016 (2.146–16.866)	0.002	6.513 (1.969–21.542)	<0.001	5.672 (2.254–14.275)	0.001	5.793 (2.064–16.259)
WT1 mutation	0.358	0.761 (0.425–1.362)	–	–	0.779	1.090 (0.595–1.997)	–	–
NPM1 mutation	0.273	1.682 (0.663–4.264)	–	–	0.488	1.441 (0.514–4.040)	–	–
DNMT3A mutation	<0.001	4.799 (2.195–10.491)	0.004	3.922 (1.529–10.000)	<0.001	6.540 (2.942–14.538)	0.028	6.045 (1.100–5.263)
C-KIT mutation	0.445	0.574 (0.139–2.380)	–	–	0.542	0.641 (0.154–2.672)	–	–
FLT3-ITD mutation	0.089	2.443 (0.873–6.838)	–	–	0.015	3.194 (1.250–8.163)	0.986	–
IDH1/2 mutation	0.100	2.689 (0.827–8.804)	–	–	0.002	5.230 (1.836–14.897)	0.487	–
AML1-ETO mutation	0.026	0.200 (0.049–0.827)	–	–	0.021	0.096 (0.013–0.699)	0.09	–

OS overall survival, LFS leukemia-free survival, HR hazard ratio, CI confidence interval, WBC white blood cells, BM Blasts bone marrow blasts

Treatment regimen (with chemotherapy-only vs. with transplantation), gene mutations (mutant vs. wild-type).